NCT05184738 (PEPTIDICAN21) is a NA clinical trial of Experimental Treatment, Oligomeric nutritional formula in Anorexia Nervosa, sponsored by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud.

What drugs are being tested in NCT05184738?

Interventions in NCT05184738: Experimental Treatment, Oligomeric nutritional formula, Control Treatment.

What condition does NCT05184738 study?

NCT05184738 studies Anorexia Nervosa.

Is NCT05184738 still recruiting?

NCT05184738 is currently completed. Last updated 14 February 2025.

Last reviewed 2025-02-14 · How we verify

NCT05184738: PEPTIDICAN21

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nutritional Supplements in Patients with Anorexia Nervosa

Completed NA Last updated 14 February 2025

What this trial tests

NA trial testing Experimental Treatment, Oligomeric nutritional formula in Anorexia Nervosa in 42 participants. Completed in 22 May 2022.

Timeline

15 October 2021

Primary endpoint
12 March 2022

22 May 2022

Quick facts

Lead sponsor	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	15 October 2021
Primary completion	12 March 2022
Estimated completion	22 May 2022
Sites	1 location across Spain

Drugs / interventions tested

Experimental Treatment, Oligomeric nutritional formula
Control Treatment

Conditions studied

Anorexia Nervosa — all drugs for Anorexia Nervosa →

Sponsor

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud — full company profile →

Who can join

Adults 12 to 40, any sex, with Anorexia Nervosa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Anorexia nervosa causes gastroparesis, constipation, and can lead to elevated liver enzymes. It is often necessary to supplement the diet of patients with nutritional formulas. The ingestion of a peptide formula, with partially hydrolyzed protein and rich in medium chain triglycerides, could favor its digestion and absorption, improving its tolerance and acceptance by the patient, compared to a polymeric formula.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Comparison of the digestive tolerance of an oligomeric versus a polymeric oral nutritional supplement in people with anorexia nervosa. A randomised crossover clinical trial.
Ruiz García I, Porras Pérez N, García Torres F, Olivas Delgado L, et al · · 2025 · PMID 40164776 · DOI 10.1038/s41430-025-01608-y
Comparison of the digestive tolerance of an oligomeric versus a polymeric oral nutritional supplement in people with anorexia nervosa. A randomised crossover clinical trial.
Olveira G, García IR, Pérez NP, Torres FG, et al · · 2024 · DOI 10.21203/rs.3.rs-3778105/v1

Verify or expand the search:

Other recruiting trials for Anorexia Nervosa

Currently open trials in the same condition.

NCT07169747 — Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young · Phase 2 · recruiting
NCT07237607 — Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders · NA · recruiting
NCT07188155 — Adapting Exposure for Adolescent AN · NA · recruiting
NCT07143981 — The Fecal Microbiome Transplant (FMT) Study for Anorexia Nervosa · recruiting
NCT07311356 — Prognosis of Early-onset Anorexia Nervosa · recruiting

Other Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud trials

Trials by the same sponsor.

NCT06852014 — Effects of Peptamen 1.6 in Malnourished Patients (or at Risk) With Pancreatic Neoplasia Undergoing Cephalic Pancreaticod · NA · recruiting
NCT06936501 — The Cooling Sensation Safe Deglution Study · NA · recruiting
NCT07192445 — Usability of Graphic Medicine in Psychology Education · NA · completed
NCT06558526 — Pectin Intervention Study and Long-term Follow-up in Lipid Transfer Proteins Allergic Patients · NA · recruiting
NCT06251232 — Proof-of-concept to Evaluate the Efficacy and Safety of Prednisone in Idiosyncratic Hepatotoxicity · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05184738 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Last refreshed: 14 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05184738.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing